Table 1.
Demographics, comorbidities, and plasma SARS-CoV-2 nucleocapsid antigen concentrations for individuals with plasma samples drawn ±1 day from diagnostic respiratory NAAT (n = 74).
| Covariatea | Overall (n = 74) | Outpatient (n = 18) | Inpatientb (n = 30) | ICU (n = 26) | P valuec |
|---|---|---|---|---|---|
| Age, years | 56 (37–75) | 43 (31–63) | 60 (39–82) | 61 (40–72) | 0.07 |
| Sex (female) | 39 (52.7) | 10 (55.6) | 19 (63.3) | 10 (38.5) | 0.2 |
| Diabetes | 27 (36.5) | 4 (22.2) | 10 (33.3) | 13 (50.0) | 0.1 |
| Hypertension | 31 (41.9) | 5 (27.8) | 11 (36.7) | 15 (57.7) | 0.1 |
| Obesity | 31 (41.9) | 6 (33.3) | 13 (43.3) | 12 (46.2) | 0.7 |
| Days Sxd | 7 (3–10) | 7 (4–10) | 5 (2–10) | 8 (3–11) | 0.3 |
| Resp. Cte | 25.8 (18.6–30.9) | 28.4 (16.3–33.2) | 25.8 (18.7–31.1) | 23.4 (19.1–29.4) | 0.6 |
| Log10 Agf | 6.2 (5.4–6.7) | 5.4 (3.9–6.0) | 6.0 (5.4–6.5) | 6.6 (6.1–7.2) | <0.001 |
a
Continuous variables reported as median (interquartile range); categorical variables reported as N (%).
b
Inpatients excluding those requiring intensive care.
c
Kruskal-Wallis test.
d
Days from symptom onset.
e
Respiratory NAAT Ct.
f
Log10 Ag, Log10 nucleocapsid antigen concentration (fg/mL).